2,6-cis-2,6-dimethyl-1-(2-hydroxyethyl)piperidine | 10561-22-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2,6-cis-2,6-dimethyl-1-(2-hydroxyethyl)piperidine
• 英文别名: 2,6-dimethyl-1-piperidineethanol；2-(2r,6c-dimethyl-piperidino)-ethanol；2-(2r,6c-Dimethyl-piperidino)-aethanol；2-(cis-2,6-Dimethylpiperidyl)ethan-1-ol；2-[(2R,6S)-2,6-dimethylpiperidin-1-yl]ethanol
• CAS: 10561-22-5
• 化学式: C₉H₁₉NO
• mdl: MFCD15732034
• 分子量: 157.256
• InChiKey: NJBXJPLWOZJAJJ-DTORHVGOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,6-cis-2,6-dimethyl-1-(2-hydroxyethyl)piperidine 生成 1-benzoyloxy-2-(2r,6c-dimethyl-piperidino)-ethane; hydrochloride
  参考文献：
  名称：

  Dialkylaminoalkyl 4-Alkylaminobenzoates

  摘要：

  DOI：

  10.1021/ja01159a070
• 作为产物：
  描述：

  (2R,6S)-2,6-dimethylpiperidine 在 lithium aluminium tetrahydride 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 2,6-cis-2,6-dimethyl-1-(2-hydroxyethyl)piperidine
  参考文献：
  名称：

  具有高血脑屏障通透性的一系列新型有效口服活性腺苷A1受体拮抗剂的设计，合成和生物学评估。

  摘要：

  合成了一系列新颖的3-（2-取代-3-氧代-2,3-二氢哒嗪-6-基）-2-苯基吡唑并[1,5-a]吡啶（5-38），并对其体外进行了评估腺苷A1和A（2A）受体结合活性以及大鼠肝脏的体外代谢，以寻找口服活性化合物。大多数测试化合物是具有高A1选择性的有效腺苷A1受体拮抗剂，并且羰基衍生物（5-11）的A1亲和力和A1选择性特别高。特别地，化合物7是具有高A1选择性（Ki ＝ 0.026nM，A（2A）/ A1 ＝ 5400）的非常有效和选择性的腺苷A1拮抗剂。就代谢稳定性而言，2-氧丙基（5），2-羟丙基（12），N-甲基乙酰胺（16），2-（哌啶-1-基）乙基（28）和1-甲基哌啶-4-基（32） （FR194921）是该系列类似物中最稳定的化合物。进一步的体内评估表明，在大鼠口服后在血浆和脑中均检测到化合物5、13、17、28和32。特别是32位患者显示出良好的血浆和大脑浓度（剂量：32

  DOI：

  10.1248/cpb.49.988

文献信息

• Synthesis and antiarrhythmic activity of .alpha.-[(diarylmethoxy)methyl]-1-piperidineethanols
  作者：Milton L. Hoefle、L. T. Blouin、R. W. Fleming、S. Hastings、J. M. Hinkley、T. E. Mertz、T. J. Steffe、C. S. Stratton、L. M. Werbel

  DOI：10.1021/jm00105a002

  日期：1991.1

  A series of alpha-[(diarylmethoxy)methyl]-1-piperidineethanols was evaluated for antiarrhythmic activity in the coronary artery ligated dog model. Structure-activity relationship studies indicated that the 2,6-dimethylpiperidine group afforded the best antiarrhythmic agents in this series and was essential for long duration of action. This investigation indicated that quaternary ammonium salts were

  评价了一系列α-[（（二芳基甲氧基）甲基] -1-哌啶乙醇在冠状动脉结扎狗模型中的抗心律失常活性。结构-活性关系研究表明，2,6-二甲基哌啶基团提供了该系列中最好的抗心律不齐药，并且对于长时间作用至关重要。该研究表明，季铵盐对于长时间的作用不是必需的。还显示出抗心律失常活性可以与由这种类型的药物引起的心动过速分开。
• Indazole compounds and methods of use thereof
  申请人：Bhagwat S. Shripad

  公开号：US20060004043A1

  公开（公告）日：2006-01-05

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseses or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防广泛的疾病和紊乱方面具有实用性，这些疾病和紊乱对激酶的抑制、调节或调控具有反应性，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病有关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛和其他疾病。因此，本发明还揭示了治疗或预防此类疾病和紊乱的方法，以及包含一种或多种吲唑化合物的药物组成物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，它们在蛋白激酶调节方面具有强效活性。因此，本发明包括口服活性分子以及可用于治疗与蛋白激酶信号转导相关的疾病或紊乱的肠外活性分子，其剂量或血清浓度较低。
• INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Bhagwat Shripad S.

  公开号：US20090099178A1

  公开（公告）日：2009-04-16

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseases or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防许多对激酶的抑制、调节或调控具有反应性的疾病和障碍方面具有用途，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉粥样硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病相关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛等。因此，本发明还揭示了治疗或预防这些疾病和障碍的方法，以及包含一种或多种吲唑化合物的制药组合物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，这些分子在调节蛋白激酶方面具有强效活性。因此，本发明包括口服活性分子和经肠道给药的活性分子，可用于治疗与蛋白激酶信号转导相关的疾病或障碍，且可用较低剂量或血清浓度。
• Indazole compounds and methods of use thereof as protein kinase inhibitors
  申请人：SIGNAL PHARMACEUTICALS, INC.

  公开号：EP2065383A1

  公开（公告）日：2009-06-03

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseses or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶液剂和水合物。吲唑化合物可用于治疗或预防对激酶的抑制、调节或调控有反应的多种疾病和失调，如炎症性疾病、异常血管生成及其相关疾病、癌症、动脉粥样硬化、心血管疾病、肾脏疾病、自身免疫性疾病、黄斑变性、与疾病相关的消瘦、与石棉相关的疾病、肺动脉高压、糖尿病、肥胖症、疼痛等。因此，本发明还公开了治疗或预防此类疾病和失调的方法，以及包含一种或多种吲唑化合物的药物组合物。本发明部分基于对一类新型 5-三唑取代的吲唑分子的发现，该类分子在调节蛋白激酶方面具有强效活性。因此，本发明包括口服活性分子和肠外活性分子，这些分子可以较低的剂量或血清浓度用于治疗与蛋白激酶信号转导有关的疾病或紊乱。
• Autonomic Blocking Agents. II. Alkamine Esters and their Quaternaries
  作者：J. W. Cusic、Richard A. Robinson

  DOI：10.1021/jo50006a015

  日期：1951.12